Trials / Completed
CompletedNCT01578447
Acceptability of Depo-subQ Provera 104 in Uniject vs. Intramuscular Depo-Provera Among HIV+ Women & Providers, Uganda
Acceptability of Depo-subQ Provera 104 in Uniject Versus Intramuscular Depo-Provera Among HIV-positive Women and Family Planning Providers in Rakai, Uganda
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 356 (actual)
- Sponsor
- Johns Hopkins Bloomberg School of Public Health · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess acceptability and side effects of a low-dose injectable contraceptive formulation which is delivered under the skin (subcutaneously), as compared with injectable contraception delivered into the muscle (intramuscularly) among adult HIV-positive women who attend mobile clinics for HIV care and wish to use injectable contraception. The investigators will also assess experiences experiences delivering these two types of injections among health care providers working within the HIV care clinics.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DepoSubQ Provera 104 in Uniject | DepoSubQ Provera 104 in Uniject |
| DRUG | Intramuscular DMPA | Intramuscular DMPA |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2012-04-17
- Last updated
- 2014-09-18
Locations
1 site across 1 country: Uganda
Source: ClinicalTrials.gov record NCT01578447. Inclusion in this directory is not an endorsement.